Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents

Stents Clinical Trial

— OCTOPUS  

Official title:

Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01056744
• Other study ID #: UKJ-TCP-1
• Status: Completed
• Phase: Phase 4
• First received: January 25, 2010
• Last updated: February 25, 2013
• Start date: June 2009
• Est. completion date: June 2012

Study information

• Verified date: February 2013
• Source: University of Jena
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

Background:

Safety concerns regarding use of drug eluting stent systems (DES) are related mostly to late stent thrombosis, which is facilitated by incomplete stent endothelial coverage. Specific information about time course and amount of endothelial strut coverage of different DES is required, in order to further refine the concept of antiplatelet therapy after DES implantation. Optical coherence tomography (OCT) is emerging as a new gold standard for endovascular imaging of stents, atherosclerosis progression, vulnerable plaque and neointimal proliferation. Very limited OCT data about endothelial coverage of DES are currently available. Aim of this study is a comparative evaluation of XIENCE V® everolimus eluting stent (Abbot Vascular) and of the bare metal stent (BMS) Coroflex® Blue postdilated with the drug-eluting balloon (DEB) SeQuent® Please (paclitaxel-eluting balloon, B. Braun Melsungen AG) in terms of endothelial coverage and neointimal proliferation using OCT.

Study Design:

A number of 80 patients scheduled for elective percutaneous coronary intervention (PCI) with a native coronary stenosis suitable for DES implantation and OCT imaging are openly randomized 1:1 to either XIENCE V® or Coroflex® Blue/Sequent® Please. The study is prospectively conducted at a university high-volume PCI center with OCT expertise (Jena, Germany). Angiographic follow-up and OCT imaging with motorized pull-back at 1 mm/s are planned in all patients 6 months after implantation of the study stents. OCT endpoints are: (1) endothelial coverage, expressed as % of struts without coverage and % of stent length containing non-covered struts, and respectively (2) neointimal proliferation, given as % neointimal volumetric proliferation within the whole stent and also as focal peak % neointimal area proliferation. The study is not powered for clinical endpoints, which are: subacute or late stent thrombosis and need for revascularization of the stent segment. Given the high number of measurements (15 cross-section images / 1 mm stent length), OCT endpoints are likely to reach significance at the level P < 0.05 even at a follow-up drop-out rate up to 20%.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: June 2012
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Established indication to PCI according to the guidelines of American Heart Association and American College of Cardiology

• Age > 18 years, written consent

• Native coronary lesion suitable for stent placement and OCT imaging

Exclusion Criteria:

1. General exclusion criteria:

• Pregnancy and breast feeding mother

• Co-morbidity with an estimated life expectancy of < 50 % at 1 year

• Scheduled major surgery in the next 6 months

• Not able to give informed written consent or non-compliance

• Participation in other PCI trial

2. Procedural exclusion criteria:

• Acute coronary syndromes and cardiogenic shock

• Previous subacute or late coronary stent thrombosis

• Known non-responsiveness / allergy to aspirin or thienopyridines

• Known allergy against everolimus or against taxol derivates

3. Angiographic exclusion criteria:

• Culprit lesion within the proximal 10 mm of the right or left coronary artery

• Saphenous vein grafts

• Estimated stent length > 30 mm

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neointimal Proliferation
• Stents

Intervention

Device:
• Percutaneous coronary intervention with stent implantation
Percutaneous coronary intervention with implantation of either: - a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group), or: - a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)

Locations

Country	Name	City	State
Germany	University Hospital of Jena, 1st Medical Department, Division of Cardiology	Jena

Sponsors (4)

Lead Sponsor	Collaborator
University of Jena	Abbott Vascular, B. Braun Melsungen AG, Boston Scientific Corporation

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Endothelial coverage of the stent struts assessed by optical coherence tomography		6 months	No
Secondary	Neointimal proliferation within the stent assessed by optical coherence tomography		6 months	No
Secondary	Subacute or late thrombosis of the study stent		6 months	Yes
Secondary	Need for revascularization of the vessel segment containing the study stent		6 months	No